<code id='CA173822CB'></code><style id='CA173822CB'></style>
    • <acronym id='CA173822CB'></acronym>
      <center id='CA173822CB'><center id='CA173822CB'><tfoot id='CA173822CB'></tfoot></center><abbr id='CA173822CB'><dir id='CA173822CB'><tfoot id='CA173822CB'></tfoot><noframes id='CA173822CB'>

    • <optgroup id='CA173822CB'><strike id='CA173822CB'><sup id='CA173822CB'></sup></strike><code id='CA173822CB'></code></optgroup>
        1. <b id='CA173822CB'><label id='CA173822CB'><select id='CA173822CB'><dt id='CA173822CB'><span id='CA173822CB'></span></dt></select></label></b><u id='CA173822CB'></u>
          <i id='CA173822CB'><strike id='CA173822CB'><tt id='CA173822CB'><pre id='CA173822CB'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:explore    - browse:92
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          hotspot